19 February 2021 - The EMA on Friday announced it will pilot an early engagement program to bring patient and consumer groups to the table with its human medicines committee earlier in the evaluation process.

In its proposal for the pilot, EMA says there are “missed opportunities” for its Committee for Medicinal Products for Human Use to incorporate patient perspectives into its reviews, as patient input is typically sought late in the process and often after major objections have been identified. Left unresolved, major objections to a medicine can prevent a medicine from being authorised.

Read Regulatory Affairs Professional Society article